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Abstract
Context: Hemolytic uremic syndrome (HUS), being more prevalent in infants and children, is recognized by a triad of acute kidney
injury, microangiopathic hemolytic anemia, and thrombocytopenia. It is classified according to the underlying disorders, such as
infection, systemic, metabolic disorder, or complement dysregulation. It has a high rate of morbidity and mortality. Many types of
treatment, such as conservative management, plasma exchange, regular plasma infusion, and even a new expensive medication,
“Ecluzimab”, have been suggested. The aim of this systematic review is to estimate the incidence and prevalence of HUS (according
to diarrhea positive or negative samples). In addition, the study will investigate the clinical presentation and the outcome of Iranian
patients.
Evidence Acquisition: The following data bases will be explored for articles published between years 1985 and 2016, PubMed, EM-
BASE, OVID, SCOPUS, Web of Sciences, Google Scholar, Google, barakatkns.com, MagIran, SID, dociran, PDFiran, and ganj.irandoc. Be-
sides, all online university databases will be searched for theses and abstracts of local or international congresses; a manual search
will be performed to identify pertinent cross references. Systematic review or meta-analysis, longitudinal and cohort studies, cross-
sectional, case-control, and epidemiological studies will be included in this review. Relevant conference proceedings, theses or un-
published data will also be considered. The retrieved data should comprise of proportions, incidence, prevalence, geographical dis-
tribution, mortality and morbidity rates (i.e. dialysis and central nervous system involvement). A meta-analysis will be performed if
3 similar studies are found. If sufficient data is extracted, subgroup analysis will be performed for age, gender, acute kidney injury,
dialysis, and death.
Results: The results of the current study could have implications for health policies, practice, research, and medical education: The
data could improve clinical and health care decisions, allow estimation of the number of patients that require new medication, and
could direct future research design in this field.
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1. Context
Hemolytic uremic syndrome (HUS) is defined by
thrombocytopenia, acute kidney injury, and microangio-
pathic hemolytic anemia. Historically, it was identified by
a positive diarrhea and negative HUS. Atypical hemolytic
uremic syndrome (aHUS) is an old terminology used for
describing non-infectious-induced HUS in infants and
children (1). Gaining an understanding of the concealed
mechanisms and pathophysiology, different etiologies,
including bacteria or viral infections, metabolic disorders,
vacuities, medication, and complement dysregulation
have been identified (2-5).
Hemolytic uremic syndrome is one of the leading
causes of acute kidney injury in Iranian children (6, 7). De-
layed improvement of kidney function has been reported
(8). This was found in approximately one third of cases
who died (9, 10). Furthermore, HUS affects various organs
and there is a few studies on morbidity in Iranian children:
i.e. cholelithiasis presented with obstructive jaundice (11),
delayed dilated cardiomyopathy responded to inotropic
agents and diuretics (12), and diffuse brain ischemia (13),
Gastrointestinal perforation, intussusceptions, and gan-
grene lead to surgical exploration (14).
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The overall incidence of diarrhea negative HUS is 0.5
to 2.1 per 100000 per years (15, 16). The incidence rate of
HUS /1000000 person-years was reported as 2.7 in the US,
2.1 in United Kingdome, and 2.1 in Canada (17). European
registry of aHUS reported a pediatric prevalence of 3.3 cases
one million individuals (18). Karimi et al. reported a declin-
ing incidence of HUS in Southwest of Iran with an annual
incidence of 8 cases per one million children younger than
15 years in 1993 to 1.1 in 2003 (19). The overall mortality rate
of HUS in Iran is high, between 19.5% and 35% (20).
2. Research Question and Analytic Framework
The proportion, prevalence, and incidence of HUS (D
positive and negative HUS) in Iran will be estimated in this
review. Moreover, the etiology and final outcome of HUS
will be studied.
3. Protocol and Registration
The protocol has been registered with the interna-
tional prospective register of systematic reviews ( PROS-
PERO) (21), registration number CRD42017059086 , and ap-
proved by the ethics committee of Iran University of Medi-
cal Sciences, number code: 96-02-225-31405. The Preferred
Reporting Items for systematic review and meta-
analysis (PRISMA)-Protocols statement was followed
through the study.
4. Eligibility Criteria
All patients with hemolytic uremic syndrome or renal
biopsy indicating typical pathological findings of throm-
botic microangiopathy (TMA) will be included. The defi-
nition of hemolytic uremic syndrome is microangiopathic
hemolytic anemia, thrombocytopenia, and acute renal fail-
ure. All cases with atypical (diarrhea negative), diarrhea
positive hemolytic uremic syndrome, and TMA will be
included. Microangiopathic hemolytic anemia is identi-
fied by hemoglobin of less than the lower limit of nor-
mal for age, high reticulocyte count, elevated level of lac-
tic dehydrogenase (LDH) when the coombs test is nega-
tive. Thrombocytopenia is defined by platelet count of less
than 150000/micro liters, and renal injury is delineated by
serum creatinine of more than the upper limit of normal
for age. This study will include systematic reviews or meta-
analysis, longitudinal and cohort studies, cross-sectional,
case-control, and epidemiological studies. Pertinent con-
ference proceedings, theses or unpublished data will also
be evaluated. Experimental studies, narrative reviews, and
case reports, and thrombotic thrombocytopenic purpura
will be excluded.
5. Types of Participants
The outcome of interest is the proportion of aHUS, final
outcome including end stage renal disease (ESRD), morbid-
ity, or death.
6. Data Source and Search Strategy
The following data bases will be searched for published
articles, PubMed, EMBASE, Google Scholar, Google, OVID,
SCOPUS, Web of Sciences, barakatkns.com, MagIran, SID,
dociran, PDFiran, and ganj.irandoc. Moreover, databases
of each medical university in Iran will be searched for rel-
evant theses and records. In order to obtain missed data, a
manual search will be performed for cross references, the
abstracts of international, regional, or local congresses.
The authors will be contacted to obtain more details in case
of missing information and to collect unpublished data
from known Iranian investigators pundit in HUS. Studies
issued between January 1985 and January 2016 will be con-
sidered. Before the final analyses the researchers will re-
peat the search for recent admissible studies to be covered
in the review.
7. Provisional Search Strategy for Pubmed
Atypical hemolytic uremic syndrome “(Mesh) AND
“Iran”(Mesh)/”Hemolytic-Uremic Syndrome”(Mesh)) AND
“Iran”(Mesh)/”Thrombotic Microangiopathies”(Mesh)
AND “Iran”(Mesh)/ (“glomerulonephritis”(MeSH Terms)
OR “glomerulonephritis”(All Fields)) AND “Iran”(Mesh).
“acute kidney injury”(MeSH Terms) OR Acute renal fail-
ure, “renal insufficiency, chronic”(MeSH Terms), chron-
ic”(MeSH Terms) OR chronic renal disease, “renal dialy-
sis”(MeSH Terms) OR “dialysis”(MeSH Terms).
The comparable Persian terms for the above quoted
words will be used to survey the articles in Iranian
database.
8. Study Selection
After the preliminary pilot search, NH, MS, and FJ will
independently review the abstracts and articles to select
suitable studies. Disagreement between reviewers will be
solved by consensus or by NH. The STROBE statement will
be used to assess the quality of studies and their eligibil-
ity as previously explained (22, 23). The researchers will
use PRISMA flowchart to present the process of article se-
lection.
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9. Data Extraction and Risk of Bias Assessment
The researchers have designed a structured data ab-
straction form and one author will extract data that includ-
ing authors’ name, title of study, journal, year, volume,
number, page; language of study, center of study, type of
study, period of study, sample size, patient information
(age, disease and gender), the region of study, length of fol-
low up, outcome (recovery, HUS, death and unreported),
and funding sources.
Three reviewers will independently assess the risk of
bias by using the tool developed by Hoy et al. (22-24). Dis-
agreement between reviewers will be solved by consensus
or by the third author (NH).
10. Data Synthesis and Statistical Analysis
The authors will consider performing meta-analyses
when at least 3 studies of low or medium risk of bias ex-
ist and have similar population, design, and outcomes.
The researchers are aware of the probable biases of meta-
analyses that include a small number of articles; before
calculating a pooled summary estimate in a meta-analysis,
the researchers will carefully consider the heterogeneity
across studies. An anecdotal synthesis of the data will be
given. The researchers will calculate point prevalence and
incidence. If studies could be assembled, the researchers
will pool results for studies that have used the same tech-
nique and the same outcome. A random-effects meta-
analysis and risk ratios for binary outcomes will be used.
The researchers will calculate 95% confidence intervals.
If the studies cannot be clustered, both the Chi-square
test (P value of 0.1 set for clinical significance) and the I-
squared statistic will be used to evaluate heterogeneity be-
tween the studies in effect measures (I-squared value of
more than 50% indicates substantial heterogeneity) (25).
The researchers will investigate the potential causes for
heterogeneity. Funnel plots and Kendall’s test will be used
to gauge publication bias.
If data are sufficient, the researchers will conduct
subgroup-analyses testing for differences between age
groups (children-adults), regions, diarrhea positive and
negative, acute kidney injury, and chronic kidney disease.
11. Discussion
This protocol aims at investigating the incidence of
hemolytic uremic syndrome and its subtypes in Iran. The
review will focus on morbidity (chronic kidney disease and
ESRD) and mortality.
There are currently no figures of HUS incidence or
prevalence in Iranian children. The epidemiological study
of HUS would help promote laboratory methods to accel-
erate the most accurate diagnosis of the underlying dis-
ease, as different types of HUS have various pathogenesis
and management (26).
Delay in diagnosis and treatment has a crucial impact
on quality of life and increases the risk of morbidity and
mortality (27, 28).
No surveillance strategy has been conducted to detect
shiga-toxin in suspicious diarrhea cases in Iran so far. Cor-
rect and on time diagnosis is decisive for appropriate man-
agement and follow up. In addition, a few centers in Iran
afford to measure complement component to detect atyp-
ical HUS due to complement dysregulation. However, re-
lying on this approach per se has its limitations and draw-
backs. The panel is not complete yet and a normal result
does not eliminate neither inherited nor acquired comple-
ment dysregulation type of HUS. An accurate diagnosis is
paramount to reduce morbidity with on time treatment
using novel medication that inhibit terminal component.
The findings of this systematic review will be published in
a peer-reviewed journal and presented in conferences. This
systematic review and meta-analysis will estimate the fre-
quency of HUS (D+ or D-) in Iran. This figure could help
clinical and health care administrative processes. Further-
more, it could assist with the unfolding of the path for
forthcoming research design and direction in this field.
12. Implication for Health Policy, Practice, Research,
and Medical Education
The proposed research could improve clinical and
health care decisions, allow estimation of patients requir-
ing new medication, and direct future research design in
this field.
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